Taken together, our findings revealed that TMEM158 is upregulated in GBM and promotes GBM tumorigenesis and aggressiveness by activating the STAT3 signaling pathway, highlighting that it may represent an effective therapeutic target in GBM. Here, TMEM158 is linked to glioblastoma.